GBT Announces New Employment Inducement Grants
April 03 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on April 1, 2020, the compensation committee of GBT’s board of
directors granted three new employees restricted stock units for an
aggregate of 10,550 shares of the company’s common stock. These
awards were made under GBT’s Amended and Restated 2017 Inducement
Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and amended in June 2019.
About Global Blood Therapeutics Global
Blood Therapeutics (GBT) is a biopharmaceutical company
dedicated to the discovery, development and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of SCD. GBT is also advancing its pipeline program
in SCD with inclacumab, a p-selectin inhibitor in development to
address pain crises associated with the disease. In addition, GBT’s
drug discovery teams are working on new targets to develop the next
generation of treatments for SCD. To learn more, please visit
www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024